Monthly Archives: June 2011

Planning Beyond the Petri Dish: A Pfizer Case Study

Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a significant role […]
Posted in Emerging Markets, Global, R&D | Tagged , , , , , , , | Leave a comment

Study Points to Dramatic Drop In R&D Expenditure

Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
Posted in Global, Guest Blog, R&D | Tagged , , , , | 1 Comment

Europe: New Vision, Old Ideas

Europe: New Vision, Old Ideas The European industry is making saintly noises about collaboration, but vestiges of the old dogma remain, says Reflector. If you want to know what the Vatican is thinking, a pontifical high mass is a good place to start. If you want to know what the European pharmaceutical industry is thinking, […]
Posted in Europe, Guest Blog, Regulatory | Tagged , , , , | Leave a comment

Supreme Court Strikes down Vermont Law, Upholds Rep Free Speech

June 23rd was a good day for the pharmaceutical industry. The Supreme Court released two decisions that largely went pharma’s way. There was much rejoicing across the industry, and for good reason, business as usual won out. In PLIVA v. Mensing, the Court ruled that generic drug companies should comply with federal regulations instead of […]
Posted in Legal | Tagged , , , | Leave a comment

Supreme Court Ruling Makes Generics More Dangerous

Today’s Supreme Court ruling on Pliva v. Mensing, which held that generic drug companies are not responsible for updating drug labels in light of new safety concerns, makes taking generic drugs a riskier proposition for consumers, Justice Sonia Sotomayor wrote in her dissenting opinion. Justices Stephen Breyer, Elena Kagan and Ruth Bader Ginsburg also dissented […]
Posted in Corporate Responsibility, Legal | Tagged , | 1 Comment
  • Categories

  • Meta